// Anecdotal evidence

Anecdotal evidence

Open discussions where the mechanism is real but consumer claims race ahead of the data.

Anecdote ≠ evidence. Items here are conversations worth having, not clinical recommendations.

Learner question · common patient scenario

My gut test says I have 'low diversity' and I need their supplement subscription. Should I worry?

1. Is 'low diversity' meaningful?

Diversity is a real ecological metric, but consumer test reference ranges are not clinically validated. Your 'diversity score' depends on the DNA extraction method, sequencing platform, and database used — not just your biology.

2. Do you need their supplements?

No consumer microbiome test has been FDA-cleared for diagnostic use. The supplement recommendations are based on proprietary algorithms without published validation studies. A high-fiber, varied diet is more likely to improve diversity than any supplement subscription.

Bottom line

Real metric, unvalidated test, unproven intervention. Eat more fiber and fermented foods before spending on supplements.

Learner question · clinical counseling scenario

Should I take probiotics after every antibiotic course to 'rebuild' my microbiome?

1. Do probiotics help after antibiotics?

S. boulardii and L. rhamnosus GG have evidence for preventing antibiotic-associated diarrhea specifically. But 'rebuilding the microbiome' with a random probiotic is not supported — Zmora et al. showed that probiotic colonization is person-specific, and Suez et al. showed probiotics can actually delay microbiome recovery in some people.

2. What should I recommend instead?

For AAD prevention in high-risk patients, specific strains (S. boulardii CNCM I-745) are reasonable. For general recovery, a varied diet rich in fiber and fermented foods is better supported than supplements.

Bottom line

Strain-specific probiotics prevent AAD. Generic 'rebuild' probiotics may do nothing or delay recovery. Diet is the better bet.

Learner question · dietary counseling

Are all fermented foods probiotics? My patient eats kimchi daily and thinks it's treating her IBS.

1. Fermented ≠ probiotic

For a product to be a probiotic, it must contain live, characterized organisms shown to confer a health benefit. Most commercial fermented foods (kimchi, sauerkraut, kombucha) have not been tested for specific health outcomes at defined doses. They may contain live cultures, but 'probiotic' requires clinical evidence for specific strains.

2. Are fermented foods still beneficial?

Yes — the Stanford study (Wastyk 2021) showed fermented foods increased microbial diversity and decreased inflammatory markers. But this was a dietary intervention study, not a test of specific products for specific diseases like IBS. Fermented foods are part of a healthy diet, not a medication.

3. What about her IBS?

IBS management should follow NICE/AGA guidelines. Some fermented foods may worsen IBS symptoms (high FODMAP: kombucha, certain yogurts). The only probiotic with reasonable IBS evidence is B. infantis 35624 for global symptoms. Diet is better managed via low-FODMAP with dietitian guidance.

Bottom line

Fermented foods are a healthy dietary choice, not a probiotic therapy. For IBS, follow structured dietary guidance and strain-specific evidence.

Learner question · common patient scenario

My functional medicine practitioner diagnosed me with 'leaky gut' and put me on 15 supplements. Should I continue them?

1. Is 'leaky gut' real?

Intestinal permeability is a real, measurable biological variable that changes in celiac disease, IBD, critical illness, and some IBS subtypes. 'Leaky gut syndrome' as a standalone diagnosis causing fatigue, brain fog, autoimmunity, and obesity is not recognized by any medical guideline.

2. What about the supplements?

Common 'leaky gut' supplements include L-glutamine, collagen, zinc carnosine, slippery elm, and digestive enzymes. Most lack RCT evidence for improving intestinal permeability in clinical populations. L-glutamine has some evidence in critical illness (ICU), not in outpatient 'leaky gut.' The cost-benefit ratio is unfavorable.

3. What should you actually do?

If a patient has genuine symptoms, pursue evidence-based workup: celiac serology, inflammatory markers, colonoscopy if indicated. Treat the underlying condition, not a marketing label.

Bottom line

Intestinal permeability is real biology; 'leaky gut syndrome' is a marketing diagnosis. Investigate symptoms through evidence-based pathways, not supplement protocols.

Learner question · obstetric counseling

Should I do vaginal seeding after my C-section to give my baby a better microbiome?

1. What is vaginal seeding?

Swabbing a newborn with maternal vaginal fluid after C-section to mimic vaginal birth microbiome exposure. The idea: C-section babies miss vaginal Lactobacillus colonization and get skin-flora colonization instead.

2. What does the evidence say?

Dominguez-Bello (2016) showed partial restoration of vaginal-like microbiota in seeded C-section babies at one month. But no study has shown this translates to improved health outcomes. The practice carries risks: unscreened maternal flora could transmit GBS, HSV, or other pathogens.

3. What do guidelines say?

ACOG (2017) and AAP do not recommend vaginal seeding outside of research protocols due to insufficient evidence of benefit and potential for harm.

Bottom line

Vaginal seeding is biologically plausible but unproven for outcomes. Not recommended outside research. Breastfeeding has stronger microbiome-seeding evidence.

Learner question · oral-systemic connection

Should I stop using mouthwash? I heard it raises blood pressure.

1. The nitrate-nitrite-NO pathway

Oral bacteria reduce dietary nitrate (from leafy greens, beets) to nitrite, which converts to nitric oxide — a vasodilator. Chlorhexidine mouthwash kills these bacteria, reducing nitrite production.

2. What's the evidence?

Small studies (Kapil 2013, Bondonno 2015) showed that twice-daily chlorhexidine use for 7 days increased systolic BP by 2–3.5 mmHg and reduced plasma nitrite. The effect is consistent but the studies are small and short-term.

3. Clinical significance?

A 2–3 mmHg population-level BP increase is meaningful epidemiologically but modest individually. For patients with resistant hypertension, it may be worth discussing. For most people, oral hygiene benefits of appropriate mouthwash use likely outweigh this effect.

Bottom line

The mechanism is real and measurable. For most patients, it's not a reason to stop mouthwash. For resistant hypertension, worth a conversation.

Learner question · patient question / self-interest

Is it worth ordering one of those at-home microbiome test kits that costs $300+?

1. What do they actually test?

Most consumer kits use 16S rRNA sequencing or shallow shotgun metagenomics on a single stool sample. They report taxonomic composition, diversity scores, and sometimes functional predictions.

2. What are the problems?

No FDA-cleared consumer kit for health guidance. Results vary by sample collection method, transit time, DNA extraction, and bioinformatics pipeline. The MBQC showed technical variance can exceed biological variance. There are no validated reference ranges for 'healthy' microbiome composition. Recommendations are based on proprietary, unpublished algorithms.

3. Is there any value?

Educational value for understanding your own microbiome composition, yes. Clinical value for guiding health decisions, no. The money is better spent on dietary diversity — more vegetables, fermented foods, and whole grains.

Bottom line

Interesting science project, poor clinical tool. No consumer test can reliably tell you what to eat or supplement. Invest in food quality instead.

Learner question · media-driven patient question

Can FMT treat obesity, depression, autism, or aging? I keep seeing these claims.

1. Where does FMT actually work?

Recurrent C. difficile infection — >85% cure rate, guideline-recommended, FDA-approved products exist. This is the only established indication.

2. What about the other conditions?

IBD (UC): modest signals in pooled-donor RCTs. Cancer immunotherapy: early Phase I/II signals. Obesity: small studies show metabolic parameter changes but no clinically meaningful weight loss. Depression/autism/aging: preclinical or case-report level only. None are ready for clinical practice.

3. Why the disconnect?

Mouse studies show dramatic effects (lean mice from obese donors, behavior changes from depressed donors). But mouse-to-human translation in the microbiome field has been poor. Add media hype and commercialization pressure, and you get a classic evidence-expectation gap.

Bottom line

FMT works spectacularly for C. diff. For everything else, we're still in the 'promising but unproven' phase. Don't confuse mouse studies with human medicine.